As shown in Figure 4, SPRY4-IT1 was aberrantly expressed in colorectal cancer, stomach adenocarcinoma, breast cancer, hepatocellular carcinoma, non-small-cell lung cancer, esophageal squamous cell carcinoma, clear cell renal cell carcinoma, and cholangiocarcinoma when compared with normal control (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001, and ns means “not significant”). This evidence concerns the gene SPRY4 and breast carcinoma.